PPAR-γ regulates osteoclastogenesis in mice

Yihong Wan, Ling Wa Chong, Ronald M. Evans

Research output: Contribution to journalArticle

378 Citations (Scopus)

Abstract

Osteoclasts are bone-resorbing cells derived from hematopoietic precursors of the monocyte-macrophage lineage. Regulation of osteoclast function is central to the understanding of bone diseases such as osteoporosis, rheumatoid arthritis and osteopetrosis. Although peroxisome proliferator-activated receptor-γ (PPAR-γ) has been shown to inhibit osteoblast differentiation, its role, if any, in osteoclasts is unknown. This is a clinically crucial question because PPAR-γ agonists, "such as thiazolidinediones -" a class of insulin-sensitizing drugs, have been reported to cause a higher rate of fractures in human patients. Here we have uncovered a pro-osteoclastogenic effect of PPAR-γ by using a Tie2Cre/flox mouse model in which PPAR-γ is deleted in osteoclasts but not in osteoblasts. These mice develop osteopetrosis characterized by increased bone mass, reduced medullary cavity space and extramedullary hematopoiesis in the spleen. These defects are the result of impaired osteoclast differentiation and compromised receptor activator of nuclear factor-κB ligand signaling and can be rescued by bone marrow transplantation. Moreover, ligand activation of PPAR-γ by rosiglitazone exacerbates osteoclast differentiation in a receptor-dependent manner. Our examination of the underlying mechanisms suggested that PPAR-γ functions as a direct regulator of c-fos expression, an essential mediator of osteoclastogenesis. Therefore, PPAR-γ and its ligands have a previously unrecognized role in promoting osteoclast differentiation and bone resorption.

Original languageEnglish (US)
Pages (from-to)1496-1503
Number of pages8
JournalNature Medicine
Volume13
Issue number12
DOIs
StatePublished - Dec 2007

Fingerprint

Peroxisome Proliferator-Activated Receptors
Osteoclasts
Osteogenesis
Bone
Osteopetrosis
rosiglitazone
Osteoblasts
Ligands
Extramedullary Hematopoiesis
Bone and Bones
Thiazolidinediones
Macrophages
Bone Diseases
Bone Resorption
Cytoplasmic and Nuclear Receptors
Bone Marrow Transplantation
Osteoporosis
Monocytes
Rheumatoid Arthritis
Spleen

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

PPAR-γ regulates osteoclastogenesis in mice. / Wan, Yihong; Chong, Ling Wa; Evans, Ronald M.

In: Nature Medicine, Vol. 13, No. 12, 12.2007, p. 1496-1503.

Research output: Contribution to journalArticle

Wan, Y, Chong, LW & Evans, RM 2007, 'PPAR-γ regulates osteoclastogenesis in mice', Nature Medicine, vol. 13, no. 12, pp. 1496-1503. https://doi.org/10.1038/nm1672
Wan, Yihong ; Chong, Ling Wa ; Evans, Ronald M. / PPAR-γ regulates osteoclastogenesis in mice. In: Nature Medicine. 2007 ; Vol. 13, No. 12. pp. 1496-1503.
@article{dd2d9818c8464c2cb7f24f2eafac8d85,
title = "PPAR-γ regulates osteoclastogenesis in mice",
abstract = "Osteoclasts are bone-resorbing cells derived from hematopoietic precursors of the monocyte-macrophage lineage. Regulation of osteoclast function is central to the understanding of bone diseases such as osteoporosis, rheumatoid arthritis and osteopetrosis. Although peroxisome proliferator-activated receptor-γ (PPAR-γ) has been shown to inhibit osteoblast differentiation, its role, if any, in osteoclasts is unknown. This is a clinically crucial question because PPAR-γ agonists, {"}such as thiazolidinediones -{"} a class of insulin-sensitizing drugs, have been reported to cause a higher rate of fractures in human patients. Here we have uncovered a pro-osteoclastogenic effect of PPAR-γ by using a Tie2Cre/flox mouse model in which PPAR-γ is deleted in osteoclasts but not in osteoblasts. These mice develop osteopetrosis characterized by increased bone mass, reduced medullary cavity space and extramedullary hematopoiesis in the spleen. These defects are the result of impaired osteoclast differentiation and compromised receptor activator of nuclear factor-κB ligand signaling and can be rescued by bone marrow transplantation. Moreover, ligand activation of PPAR-γ by rosiglitazone exacerbates osteoclast differentiation in a receptor-dependent manner. Our examination of the underlying mechanisms suggested that PPAR-γ functions as a direct regulator of c-fos expression, an essential mediator of osteoclastogenesis. Therefore, PPAR-γ and its ligands have a previously unrecognized role in promoting osteoclast differentiation and bone resorption.",
author = "Yihong Wan and Chong, {Ling Wa} and Evans, {Ronald M.}",
year = "2007",
month = "12",
doi = "10.1038/nm1672",
language = "English (US)",
volume = "13",
pages = "1496--1503",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - PPAR-γ regulates osteoclastogenesis in mice

AU - Wan, Yihong

AU - Chong, Ling Wa

AU - Evans, Ronald M.

PY - 2007/12

Y1 - 2007/12

N2 - Osteoclasts are bone-resorbing cells derived from hematopoietic precursors of the monocyte-macrophage lineage. Regulation of osteoclast function is central to the understanding of bone diseases such as osteoporosis, rheumatoid arthritis and osteopetrosis. Although peroxisome proliferator-activated receptor-γ (PPAR-γ) has been shown to inhibit osteoblast differentiation, its role, if any, in osteoclasts is unknown. This is a clinically crucial question because PPAR-γ agonists, "such as thiazolidinediones -" a class of insulin-sensitizing drugs, have been reported to cause a higher rate of fractures in human patients. Here we have uncovered a pro-osteoclastogenic effect of PPAR-γ by using a Tie2Cre/flox mouse model in which PPAR-γ is deleted in osteoclasts but not in osteoblasts. These mice develop osteopetrosis characterized by increased bone mass, reduced medullary cavity space and extramedullary hematopoiesis in the spleen. These defects are the result of impaired osteoclast differentiation and compromised receptor activator of nuclear factor-κB ligand signaling and can be rescued by bone marrow transplantation. Moreover, ligand activation of PPAR-γ by rosiglitazone exacerbates osteoclast differentiation in a receptor-dependent manner. Our examination of the underlying mechanisms suggested that PPAR-γ functions as a direct regulator of c-fos expression, an essential mediator of osteoclastogenesis. Therefore, PPAR-γ and its ligands have a previously unrecognized role in promoting osteoclast differentiation and bone resorption.

AB - Osteoclasts are bone-resorbing cells derived from hematopoietic precursors of the monocyte-macrophage lineage. Regulation of osteoclast function is central to the understanding of bone diseases such as osteoporosis, rheumatoid arthritis and osteopetrosis. Although peroxisome proliferator-activated receptor-γ (PPAR-γ) has been shown to inhibit osteoblast differentiation, its role, if any, in osteoclasts is unknown. This is a clinically crucial question because PPAR-γ agonists, "such as thiazolidinediones -" a class of insulin-sensitizing drugs, have been reported to cause a higher rate of fractures in human patients. Here we have uncovered a pro-osteoclastogenic effect of PPAR-γ by using a Tie2Cre/flox mouse model in which PPAR-γ is deleted in osteoclasts but not in osteoblasts. These mice develop osteopetrosis characterized by increased bone mass, reduced medullary cavity space and extramedullary hematopoiesis in the spleen. These defects are the result of impaired osteoclast differentiation and compromised receptor activator of nuclear factor-κB ligand signaling and can be rescued by bone marrow transplantation. Moreover, ligand activation of PPAR-γ by rosiglitazone exacerbates osteoclast differentiation in a receptor-dependent manner. Our examination of the underlying mechanisms suggested that PPAR-γ functions as a direct regulator of c-fos expression, an essential mediator of osteoclastogenesis. Therefore, PPAR-γ and its ligands have a previously unrecognized role in promoting osteoclast differentiation and bone resorption.

UR - http://www.scopus.com/inward/record.url?scp=36849034568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36849034568&partnerID=8YFLogxK

U2 - 10.1038/nm1672

DO - 10.1038/nm1672

M3 - Article

C2 - 18059282

AN - SCOPUS:36849034568

VL - 13

SP - 1496

EP - 1503

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 12

ER -